Therefore, our findings support the notion that miR-33a-5p may be used as a potential anti-bone metastatic therapeutic approach for PCa, particularly in ZEB1-induced bone metastasis of PCa. The gene discussed is ZEB1; the disease is posterior cortical atrophy.